Skip to content

Kymera Therapeutics KYMR Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-891.1%-335pp-555.8%-345pp-210.6%+134pp-344.4%-206pp
Net margin-794.1%-318pp-475.6%-289pp-187%+144pp-330.6%-193pp
Returns
Return on equity-25.8%+10.6pp-36.4%-3.2pp-33.2%-0.6pp-32.6%-5.6pp
Return on invested capital-33.1%+11.4pp-44.5%-3.7pp-40.8%-3.8pp-37%-8.4pp
Efficiency
Asset turnover0.0×0.1×-0.1×0.1×+0.1×0.1×-0.1×
Liquidity
Current ratio10.5×+2.9×7.5×+2.8×4.7×-1.1×5.9×+1.0×
Leverage
Debt-to-equity0.1×-0.1×0.1×-0.1×0.2×+0.2×0.0×
Per Share
Book value per share$18.70+67.9%$11.14+64.5%$6.77-25.5%$9.09-5.1%
Valuation
Market capitalization$6.22B+139%$2.61B+74.9%$1.49B+3.1%$1.44B-55.9%
Price / sales158.8×+103×55.4×+36.4×19×-11.9×30.9×-14.2×
Price / book3.9×+0.8×3.1×-0.7×3.8×+0.8×2.9×-4.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Kymera Therapeutics's ratios come from?
Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.